Non-viral ocular gene therapy: Potential ocular therapeutic avenues

Advanced Drug Delivery Reviews

Volumn 58, Issue 11, 2006, Pages 1224-1242

  Bloquel, C ^a   Bourges, J L ^b   Touchard, E ^a   Berdugo, M ^a   BenEzra, D ^a,c   Behar Cohen, F ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Eye disease; Gene delivery; Gene replacement; Gene therapy

Indexed keywords

DISEASES; GENES; LIPIDS; POLYMERS; POLYPEPTIDES; POSITIVE IONS; VECTOR QUANTIZATION; VIRUSES;

EYE DISEASE; GENE DELIVERY; GENE REPLACEMENT; GENE THERAPY;

DRUG THERAPY;

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; FOMIVIRSEN; IMMUNOLIPOSOME; LIPOPLEX; LIPOSOME; OLIGONUCLEOTIDE; PEGAPTANIB; PLASMID DNA; POLOXAMER; SMALL INTERFERING RNA;

CLINICAL TRIAL; CORNEA NEOVASCULARIZATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; ELECTROPORATION; EYE INFLAMMATION; GENE GUN; HUMAN; INTRAOCULAR HYPERTENSION; IONTOPHORESIS; KERATITIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; ULTRASOUND;

ANIMALS; DRUG ADMINISTRATION ROUTES; EYE DISEASES; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

EID: 33751272909     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.07.023     Document Type: Review

References (119)

1. Borras T. Recent developments in ocular gene therapy. Exp. Eye Res. 76 (2003) 643-652
2. Chaum E., and Hatton M.P. Gene therapy for genetic and acquired retinal diseases. Surv. Ophthalmol. 47 (2002) 449-469
3. Mohan R.R., Sharma A., Netto M.V., Sinha S., and Wilson S.E. Gene therapy in the cornea. Prog. Retin. Eye Res. 24 (2005) 537-559
4. Jooss K., and Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 10 (2003) 955-963
5. Bessis N., GarciaCozar F.J., and Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11 Suppl 1 (2004) S10-S17
6. Provost N., Le Meur G., Weber M., Mendes-Madeira A., Podevin G., Cherel Y., Colle M.A., Deschamps J.Y., Moullier P., and Rolling F. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Molec. Ther. 11 (2005) 275-283
7. Berdugo M., Valamanesh F., Andrieu C., Klein C., Benezra D., Courtois Y., and Behar-Cohen F. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev. 13 (2003) 107-114
8. Bochot A., Mashhour B., Puisieux F., Couvreur P., and Fattal E. Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms. J. Drug Target. 6 (1998) 309-313
9. Daheshia M., Kuklin N., Kanangat S., Manickan E., and Rouse B.T. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J. Immunol. 159 (1997) 1945-1952
10. Noisakran S., and Carr D.J. Topical application of the cornea post-infection with plasmid DNA encoding interferon-alpha1 but not recombinant interferon-alphaA reduces herpes simplex virus type 1-induced mortality in mice. J. Neuroimmunol. 121 (2001) 49-58
11. Noisakran S.J., and Carr D.J. Therapeutic efficacy of DNA encoding IFN-alpha1 against corneal HSV-1 infection. Curr. Eye Res. 20 (2000) 405-412
12. Noisakran S., Campbell I.L., and Carr D.J. Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J. Immunol. 162 (1999) 4184-4190
13. Inoue T., Inoue Y., Nakamura T., Yoshida A., Takahashi K., Shimomura Y., Tano Y., Fujisawa Y., Aono A., and Hayashi K. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis. Invest. Ophthalmol. Visual Sci. 41 (2000) 4209-4215
14. Inoue T., Inoue Y., Hayashi K., Shimomura Y., Fujisawa Y., Aono A., and Tano Y. Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis. Cornea 21 (2002) S79-S85
15. Hangai M., Tanihara H., Honda Y., and Kaneda Y. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest. Ophthalmol. Visual Sci. 39 (1998) 509-516
16. Wasmuth S., Bauer D., Yang Y., Steuhl K.P., and Heiligenhaus A. Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-alpha in herpetic stromal keratitis. Invest. Ophthalmol. Visual Sci. 44 (2003) 5228-5234
17. Stechschulte S.U., Joussen A.M., von Recum H.A., Poulaki V., Moromizato Y., Yuan J., D'Amato R.J., Kuo C., and Adamis A.P. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest. Ophthalmol. Visual Sci. 42 (2001) 1975-1979
18. Moore J.E., McMullen T.C., Campbell I.L., Rohan R., Kaji Y., Afshari N.A., Usui T., Archer D.B., and Adamis A.P. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest. Ophthalmol. Visual Sci. 43 (2002) 2905-2915
19. Singh N., Amin S., Richter E., Rashid S., Scoglietti V., Jani P.D., Wang J., Kaur R., Ambati J., Dong Z., and Ambati B.K. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest. Ophthalmol. Visual Sci. 46 (2005) 1647-1652
20. Cordeiro M.F., Mead A., Ali R.R., Alexander R.A., Murray S., Chen C., York-Defalco C., Dean N.M., Schultz G.S., and Khaw P.T. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10 (2003) 59-71
21. Kim B., Tang Q., Biswas P.S., Xu J., Schiffelers R.M., Xie F.Y., Ansari A.M., Scaria P.V., Woodle M.C., Lu P., and Rouse B.T. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165 (2004) 2177-2185
22. Angella G.J., Sherwood M.B., Balasubramanian L., Doyle J.W., Smith M.F., van Setten G., Goldstein M., and Schultz G.S. Enhanced short-term plasmid transfection of filtration surgery tissues. Invest. Ophthalmol. Visual Sci. 41 (2000) 4158-4162
23. Mo X., Yokoyama A., Oshitari T., Negishi H., Dezawa M., Mizota A., and Adachi-Usami E. Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats. Invest. Ophthalmol. Visual Sci. 43 (2002) 2401-2415
24. Kachi S., Oshima Y., Esumi N., Kachi M., Rogers B., Zack D.J., and Campochiaro P.A. Nonviral ocular gene transfer. Gene Ther. 12 (2005) 843-851
25. Dezawa M., Takano M., Negishi H., Mo X., Oshitari T., and Sawada H. Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. Micron 33 (2002) 1-6
26. Hangai M., Tanihara H., Honda Y., and Kaneda Y. In vivo delivery of phosphorothioate oligonucleotides into murine retina. Arch. Ophthalmol. 116 (1998) 342-348
27. Robinson G.S., Pierce E.A., Rook S.L., Foley E., Webb R., and Smith L.E. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4851-4856
28. Rakoczy P.E., Lai M.C., Watson M., Seydel U., and Constable I. Targeted delivery of an antisense oligonucleotide in the retina: uptake, distribution, stability, and effect. Antisense Nucleic Acid Drug Dev. 6 (1996) 207-213
29. Shen W.Y., Garrett K.L., da Cruz L., Constable I.J., and Rakoczy P.E. Dynamics of phosphorothioate oligonucleotides in normal and laser photocoagulated retina. Br. J. Ophthalmol. 83 (1999) 852-861
30. Roy S., Zhang K., Roth T., Vinogradov S., Kao R.S., and Kabanov A. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat. Biotechnol. 17 (1999) 476-479
31. Isenmann S., Engel S., Gillardon F., and Bahr M. Bax antisense oligonucleotides reduce axotomy-induced retinal ganglion cell death in vivo by reduction of Bax protein expression. Cell Death Differ. 6 (1999) 673-682
32. Garrett K.L., Shen W.Y., and Rakoczy P.E. In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J. Gene Med. 3 (2001) 373-383
33. Thaler S., Rejdak R., Dietrich K., Ladewig T., Okuno E., Kocki T., Turski W.A., Junemann A., Zrenner E., and Schuettauf F. A selective method for transfection of retinal ganglion cells by retrograde transfer of antisense oligonucleotides against kynurenine aminotransferase II. Mol. Vis. 12 (2006) 100-107
34. Shen W.Y., Garrett K.L., Wang C.G., Zhang K., Ma Z.Z., Constable I.J., and Rakoczy P.E. Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey. Lab. Invest. 82 (2002) 167-182
35. Leeds J.M., Henry S.P., Bistner S., Scherrill S., Williams K., and Levin A.A. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab. Dispos. 26 (1998) 670-675
36. Leeds J.M., Henry S.P., Truong L., Zutshi A., Levin A.A., and Kornbrust D. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab. Dispos. 25 (1997) 921-926
37. Dvorchik B.H., and Marquis J.K. Disposition and toxicity of a mixed backbone antisense oligonucleotide, targeted against human cytomegalovirus, after intravitreal injection of escalating single doses in the rabbit. Drug Metab. Dispos. 28 (2000) 1255-1261
38. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133 (2002) 484-498
39. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133 (2002) 467-474
40. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am. J. Ophthalmol. 133 (2002) 475-483
41. Shen W.Y., and Rakoczy P.E. Uptake dynamics and retinal tolerance of phosphorothioate oligonucleotide and its direct delivery into the site of choroidal neovascularization through subretinal administration in the rat. Antisense Nucleic Acid Drug Dev. 11 (2001) 257-264
42. Lingor P., Koeberle P., Kugler S., and Bahr M. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain 128 (2005) 550-558
43. Garcia-Valenzuela E., Rayanade R., Perales J.C., Davidson C.A., Hanson R.W., and Sharma S.C. Axon-mediated gene transfer of retinal ganglion cells in vivo. J. Neurobiol. 32 (1997) 111-122
44. Tanelian D.L., Barry M.A., Johnston S.A., Le T., and Smith G. Controlled gene gun delivery and expression of DNA within the cornea. Biotechniques 23 (1997) 484-488
45. Shiraishi A., Converse R.L., Liu C.Y., Zhou F., Kao C.W., and Kao W.W. Identification of the cornea-specific keratin 12 promoter by in vivo particle-mediated gene transfer. Invest. Ophthalmol. Visual Sci. 39 (1998) 2554-2561
46. Wang I.J., Carlson E.C., Liu C.Y., Kao C.W., Hu F.R., and Kao W.W. Cis-regulatory elements of the mouse Krt1.12 gene. Mol. Vis. 8 (2002) 94-101
47. Zagon I.S., Sassani J.W., Verderame M.F., and McLaughlin P.J. Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea 24 (2005) 614-619
48. Zhang E.P., Franke J., Schroff M., Junghans C., Wittig B., and Hoffmann F. Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefe Arch. Clin. Exp. Ophthalmol. 241 (2003) 921-926
49. Muller A., Zhang E.P., Schroff M., Wittig B., and Hoffmann F. Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. Graefe Arch. Clin. Exp. Ophthalmol. 240 (2002) 851-859
50. Zhang E.P., Muller A., Schulte F., Konig M.S., Sack F., Junghans C., Wittig B., and Hoffmann F. Minimizing side effects of ballistic gene transfer into the murine corneal epithelium. Graefe Arch. Clin. Exp. Ophthalmol. 240 (2002) 114-119
51. Rols M.P., Delteil C., Golzio M., Dumond P., Cros S., and Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol. 16 (1998) 168-171
52. Mir L.M., Bureau M.F., Rangara R., Schwartz B., and Scherman D. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. C. R. Acad. Sci., III 321 (1998) 893-899
53. Aihara H., and Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16 (1998) 867-870
54. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., Delaere P., Branellec D., Schwartz B., and Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4262-4267
55. Teissie J., and Rols M.P. An experimental evaluation of the critical potential difference inducing cell membrane electropermeabilization. Biophys. J. 65 (1993) 409-413
56. Gehl J., and Mir L.M. Determination of optimal parameters for in vivo gene transfer by electroporation, using a rapid in vivo test for cell permeabilization. Biochem. Biophys. Res. Commun. 261 (1999) 377-380
57. Somiari S., Glasspool-Malone J., Drabick J.J., Gilbert R.A., Heller R., Jaroszeski M.J., and Malone R.W. Theory and in vivo application of electroporative gene delivery. Molec. Ther. 2 (2000) 178-187
58. Neumann E., Kakorin S., and Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem. Bioenerg. 48 (1999) 3-16
59. Lopez A., Rols M.P., and Teissie J. 31P NMR analysis of membrane phospholipid organization in viable, reversibly electropermeabilized Chinese hamster ovary cells. Biochemistry 27 (1988) 1222-1228
60. Gehl J., Sorensen T.H., Nielsen K., Raskmark P., Nielsen S.L., Skovsgaard T., and Mir L.M. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim. Biophys. Acta 1428 (1999) 233-240
61. Bureau M.F., Gehl J., Deleuze V., Mir L.M., and Scherman D. Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim. Biophys. Acta 1474 (2000) 353-359
62. Satkauskas S., Bureau M.F., Puc M., Mahfoudi A., Scherman D., Miklavcic D., and Mir L.M. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Molec. Ther. 5 (2002) 133-140
63. Oshima Y., Sakamoto T., Kawano Y., Hata Y., Yoshikawa H., Sonoda K.H., Ishibashi T., and Inomata H. Synergistic effect of electric pulses and bleomycin on cultured rabbit subconjunctival fibroblasts. Graefe Arch. Clin. Exp. Ophthalmol. 236 (1998) 52-60
64. Sakamoto T., Oshima Y., Nakagawa K., Ishibashi T., Inomata H., and Sueishi K. Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness. Hum. Gene Ther. 10 (1999) 2551-2557
65. Oshima Y., Sakamoto T., Hisatomi T., Tsutsumi C., Sassa Y., Ishibashi T., and Inomata H. Targeted gene transfer to corneal stroma in vivo by electric pulses. Exp. Eye Res. 74 (2002) 191-198
66. Blair-Parks K., Weston B.C., and Dean D.A. High-level gene transfer to the cornea using electroporation. J. Gene Med. 4 (2002) 92-100
67. Yu W.Z., Li X.X., She H.C., He P.Y., Dong J.Q., Rui M., and Ma D.L. Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res. 35 (2003) 239-246
68. Mamiya K., Ohguro H., Ohguro I., Metoki T., Ishikawa F., Yamazaki H., Takano Y., Ito T., and Nakazawa M. Effects of matrix metalloproteinase-3 gene transfer by electroporation in glaucoma filter surgery. Exp. Eye Res. 79 (2004) 405-410
69. Ishikawa H., Takano M., Matsumoto N., Sawada H., Ide C., Mimura O., and Dezawa M. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther. 12 (2005) 289-298
70. Matsuda T., and Cepko C.L. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16-22
71. Chalberg T.W., Genise H.L., Vollrath D., and Calos M.P. phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest. Ophthalmol. Visual Sci. 46 (2005) 2140-2146
72. Kachi S., Esumi N., Zack D.J., and Campochiaro P.A. Sustained expression after nonviral ocular gene transfer using mammalian promoters. Gene Ther. 13 (2006) 798-804
73. Bloquel C., Bejjani R., Bigey P., Bedioui F., Doat M., BenEzra D., Scherman D., and Behar-Cohen F. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. FASEB J. 20 (2006) 389-391
74. McMahon J.M., and Wells D.J. Electroporation for gene transfer to skeletal muscles: current status. BioDrugs 18 (2004) 155-165
75. Glasser A., and Kaufman P.L. Accommodation and presbyopia. In: Kaufman P.L., and Alm A. (Eds). Physiology of the Eye. Clinical Application (2003), Mosby, Saint Louis, MI 197-233
76. Chen Y.X., Krull C.E., and Reneker L.W. Targeted gene expression in the chicken eye by in ovo electroporation. Mol. Vis. 10 (2004) 874-883
77. Haas K., Sin W.C., Javaherian A., Li Z., and Cline H.T. Single-cell electroporation for gene transfer in vivo. Neuron 29 (2001) 583-591
78. Azuma N., Tadokoro K., Asaka A., Yamada M., Yamaguchi Y., Handa H., Matsushima S., Watanabe T., Kida Y., Ogura T., Torii M., Shimamura K., and Nakafuku M. Transdifferentiation of the retinal pigment epithelia to the neural retina by transfer of the Pax6 transcriptional factor. Hum. Mol. Genet. 14 (2005) 1059-1068
79. Kalia Y.N., Naik A., Garrison J., and Guy R.H. Iontophoretic drug delivery. Adv. Drug Deliv. Rev. 56 (2004) 619-658
80. Oh S.Y., Leung L., Bommannan D., Guy R.H., and Potts R.O. Effect of current, ionic strength and temperature on the electrical properties of skin. J. Control. Release 27 (1993) 115-125
81. Pikal M.J. The role of electroosmotic flow in transdermal iontophoresis. Adv. Drug Deliv. Rev. 9 (1992) 201-237
82. Monteiro-Riviere N.A., Inman A.O., and Riviere J.E. Identification of the pathway of iontophoretic drug delivery: light and ultrastructural studies using mercuric chloride in pigs. Pharm. Res. 11 (1994) 251-256
83. Cullander C. What are the pathways of iontophoretic current flow through mammalian skin?. Adv. Drug Deliv. Rev. 9 (1992) 119-135
84. Pikal M.J. The role of electroosmotic flow in transdermal iontophoresis. Adv. Drug Deliv. Rev. 46 (2001) 281-305
85. Hirvonen J., Kalia Y.N., and Guy R.H. Transdermal delivery of peptides by iontophoresis. Nat. Biotechnol. 14 (1996) 1710-1713
86. Li S.K., Zhang Y., Zhu H., Higuchi W.I., and White H.S. Influence of asymmetric donor-receiver ion concentration upon transscleral iontophoretic transport. J. Pharm. Sci. 94 (2005) 847-860
87. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., and Honda Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. 23 (2004) 253-281
88. Myles M.E., Neumann D.M., and Hill J.M. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. 57 (2005) 2063-2079
89. Davies J.B., Ciavatta V.T., Boatright J.H., and Nickerson J.M. Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields. Mol. Vis. 9 (2003) 569-578
90. Asahara T., Shinomiya K., Naito T., and Shiota H. Induction of gene into the rabbit eye by iontophoresis: preliminary report. Jpn. J. Ophthalmol. 45 (2001) 31-39
91. Voigt M., de Kozak Y., Halhal M., Courtois Y., and Behar-Cohen F. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun. 295 (2002) 336-341
92. Andrieu-Soler C., Casas M., Faussat A.M., Gandolphe C., Doat M., Tempe D., Giovannangeli C., Behar-Cohen F., and Concordet J.P. Stable transmission of targeted gene modification using single-stranded oligonucleotides with flanking LNAs. Nucleic Acids Res. 33 (2005) 3733-3742
93. Liu Y., Yang H., and Sakanishi A. Ultrasound: mechanical gene transfer into plant cells by sonoporation. Biotechnol. Adv. 24 (2006) 1-16
94. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat. Rev. Drug Discov. 4 (2005) 255-260
95. Sonoda S., Tachibana K., Uchino E., Okubo A., Yamamoto M., Sakoda K., Hisatomi T., Sonoda K.H., Negishi Y., Izumi Y., Takao S., and Sakamoto T. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles. Invest. Ophthalmol. Visual Sci. 47 (2006) 558-564
96. Masuda I., Matsuo T., Yasuda T., and Matsuo N. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest. Ophthalmol. Visual Sci. 37 (1996) 1914-1920
97. Matsuo T., Masuda I., Yasuda T., and Matsuo N. Gene transfer to the retina of rat by liposome eye drops. Biochem. Biophys. Res. Commun. 219 (1996) 947-950
98. Yoon K.C., Ahn K.Y., Lee J.H., Chun B.J., Park S.W., Seo M.S., Park Y.G., and Kim K.K. Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model. Gene Ther. 12 (2005) 617-624
99. Bejjani R.A., Jeanny J.C., Bochot A., and Behar-Cohen F. The use of liposomes as intravitreal drug delivery system. J. Fr. Ophtalmol. 26 (2003) 981-985
100. Bochot A., Couvreur P., and Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res. 19 (2000) 131-147
101. Bochot A., Fattal E., Boutet V., Deverre J.R., Jeanny J.C., Chacun H., and Couvreur P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest. Ophthalmol. Visual Sci. 43 (2002) 253-259
102. Ogata N., Otsuji T., Matsushima M., Kimoto T., Yamanaka R., Takahashi K., Wada M., Uyama M., and Kaneda Y. Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system. Curr. Eye Res. 18 (1999) 261-269
103. Neuner-Jehle M., Berghe L.V., Bonnel S., Uteza Y., Benmeziane F., Rouillot J.S., Marchant D., Kobetz A., Dufier J.L., Menasche M., and Abitbol M. Ocular cell transfection with the human basic fibroblast growth factor gene delays photoreceptor cell degeneration in RCS rats. Hum. Gene Ther. 11 (2000) 1875-1890
104. Zhu C., Zhang Y., and Pardridge W.M. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest. Ophthalmol. Visual Sci. 43 (2002) 3075-3080
105. Zhang Y., Schlachetzki F., Li J.Y., Boado R.J., and Pardridge W.M. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9 (2003) 465-472
106. George A.J., Arancibia-Carcamo C.V., Awad H.M., Comer R.M., Fehevari Z., King W.J., Kadifachi M., Hudde T., Kerouedan-Lebosse C., Mirza F., Barbaros Oral H., Rayner S.A., Tan P.H., Tay E., and Larkin D.F. Gene delivery to the corneal endothelium. Am. J. Respir. Crit. Care Med. 162 (2000) S194-S200
107. Liaw J., Chang S.F., and Hsiao F.C. In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles. Gene Ther. 8 (2001) 999-1004
108. Nakamura H., Siddiqui S.S., Shen X., Malik A.B., Pulido J.S., Kumar N.M., and Yue B.Y. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis. 10 (2004) 703-711
109. Nishiyama N., Iriyama A., Jang W.D., Miyata K., Itaka K., Inoue Y., Takahashi H., Yanagi Y., Tamaki Y., Koyama H., and Kataoka K. Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer. Nat. Mater. 4 (2005) 934-941
110. Marano R.J., Toth I., Wimmer N., Brankov M., and Rakoczy P.E. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 12 (2005) 1544-1550
111. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22 (2002) 143-152
112. Drolet D.W., Nelson J., Tucker C.E., Zack P.M., Nixon K., Bolin R., Judkins M.B., Farmer J.A., Wolf J.L., Gill S.C., and Bendele R.A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17 (2000) 1503-1510
113. Ng E.W., and Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 40 (2005) 352-368
114. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
115. Ng E.W., Shima D.T., Calias P., Cunningham Jr. E.T., Guyer D.R., and Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006) 123-132
116. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., and Schwartz S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
117. Normand N., van Leeuwen H., and O'Hare P. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J. Biol. Chem. 276 (2001) 15042-15050
118. Normand N., Valamanesh F., Savoldelli M., Mascarelli F., BenEzra D., Courtois Y., and Behar-Cohen F. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol. Vis. 11 (2005) 184-191
119. Gomes Dos Santos A.L., Bochot A., Doyle A., Tsapis N., Siepmann J., Siepmann F., Schmaler J., Besnard M., Behar-Cohen F., and Fattal E. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta2 oligonucleotide improves the outcome of glaucoma surgery. J. Control. Release 112 (2006) 369-381